Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials.
Melanoma, Cancer Immunotherapy, and Innovative Therapy, Istituto nazionale Tumori Fondazione "G Pascale", Napoli, 80131, Italy. Electronic address: paolo.ascierto@gmail.com.
Paolo A
PA
Ascierto
Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospital, Sydney, Australia.
Georgina V
GV
Long
D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic / Q000379:methods*; D018450:Disease Progression; D018572:Disease-Free Survival; D023381:Endpoint Determination; D006801:Humans; D008545:Melanoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D050130:Oncolytic Virotherapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
D000074322:Antineoplastic Agents, Immunological; D047428:Protein Kinase Inhibitors